Literature DB >> 1932369

Human recombinant granulocyte-macrophage colony-stimulating factor augments viability and cytotoxic activities of human monocyte-derived macrophages in long-term cultures.

G Robin1, S Markovich, A Athamna, Y Keisari.   

Abstract

In the present study we investigated the effect of human recombinant granulocyte-macrophage CSF (GM-CSF) on the in vitro maturation of human monocytes into macrophages, and followed the biochemical and functional changes in the cells during this process. Adherent human peripheral blood monocytes cultured for up to 3 weeks in the presence of GM-CSF were examined for viability and adherence, beta-glucosaminidase activity, oxidative burst activity, expression of fucosyl-mannosyl receptors, and TNF-alpha production. The cultured monocytes increased in size and protein content and matured into macrophages within 12 to 18 days. GM-CSF treatment increased by 2.5-fold the number of adherent cells after 2 weeks in culture, but did not change the beta-glucosaminidase and oxidative burst activities of the cells compared to nontreated controls. GM-CSF increased the capacity of monocyte-derived macrophages to bind yeasts and bacteria via fucosyl-mannosyl receptors, by both augmenting the viability of the adherent cell population and by elevating the expression of such receptors per cell. GM-CSF-treated macrophage cultures also showed elevated production of TNF-alpha. The results described here showed that GM-CSF facilitated the long-term maturation of monocytes into macrophages, augmented their capacity to capture bacterial and fungal cells, and elevated the release of cytokines involved in inflammatory and granulomatous reactions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1932369

Source DB:  PubMed          Journal:  Lymphokine Cytokine Res        ISSN: 1056-5477


  7 in total

1.  Lymphocytes stimulate expression of 5-lipoxygenase and its activating protein in monocytes in vitro via granulocyte macrophage colony-stimulating factor and interleukin 3.

Authors:  W L Ring; C A Riddick; J R Baker; D A Munafo; T D Bigby
Journal:  J Clin Invest       Date:  1996-03-01       Impact factor: 14.808

Review 2.  Anti-tumoral effect of GM-CSF with or without cytokines and monoclonal antibodies in solid tumors.

Authors:  P Ragnhammar
Journal:  Med Oncol       Date:  1996-09       Impact factor: 3.064

3.  The relation between serum cytokine levels and common laboratory tests in healthy Japanese males.

Authors:  Masashi Tsunoda; Humio Tsunoda; Lucille Guevarra; David J Tollerud
Journal:  Environ Health Prev Med       Date:  2003-03       Impact factor: 3.674

4.  Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study.

Authors:  Guillaume Cartron; Lu Zhao-Yang; Marion Baudard; Tarik Kanouni; Valérie Rouillé; Philippe Quittet; Bernard Klein; Jean-Francois Rossi
Journal:  J Clin Oncol       Date:  2008-04-21       Impact factor: 44.544

5.  Increased C3 production in human monocytes after stimulation with Candida albicans is suppressed by granulocyte-macrophage colony-stimulating factor.

Authors:  A K Høgåsen; T G Abrahamsen
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

6.  Cytotoxicity of white blood cells activated by granulocyte-colony-stimulating factor, granulocyte/macrophage-colony-stimulating factor and macrophage-colony-stimulating factor against tumor cells in the presence of various monoclonal antibodies.

Authors:  P Ragnhammar; J E Frödin; P P Trotta; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1994-10       Impact factor: 6.968

7.  Anti- schistosomular activity of human monocytes/macrophages in response to interleukin-3 and granulocyte-macrophage colonystimulating factor stimulation.

Authors:  D Gold; L Nissimov; J Lengy; Y Keisari
Journal:  Mediators Inflamm       Date:  1994       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.